Abstract:It remains a big challenge to develop HDAC inhibitors effective for solid tumors. Previous studies have suggested that the feedback activation of JAK-STAT3 pathway represents a key mechanism leading to resistance to HDAC inhibitors in breast cancer, suggesting the therapeutic promise of JAK/HDAC dual inhibitors. In this work, we discovered a series of pyrrolo[2,3-d]pyrimidine-based derivatives as potent JAK and HDAC dual inhibitors. Especially, compounds 15d and 15h potently inhibited JAK1/2/3 and HDAC1/6 and displayed antiproliferative and proapoptotic activities in triple-negative breast cancer cell lines. Besides, compounds 15d and 15h also diminished the activation of LIFR-JAK-STAT signaling triggered by tumor-associated fibroblasts, which suggests that these compounds could potentially overcome the drug resistance caused by the tumor microenvironment. More importantly, compound 15d effectively inhibited the tumor growth in MDA-MB-231 xenograft tumor model. Overall, this work provides valuable leads and novel antitumor mechanisms for the treatment of the SAHA-resistant triple-negative breast cancers.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02111?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02111</a>.Supporting tables; 1H NMR, and 13C NMR of all target compounds; HPLC spectra and HRMS of the representative compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_001.pdf">PDF</a>)Molecular formula stings (CSV) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_002.csv">CSV</a>)Predicted binding mode of 6a in the ATP pocket of JAK2; surface representation of 6a in the ATP pocket of JAK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_003.pdb">PDB</a>)Predicted binding mode of 15d in the ATP pocket of JAK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_004.pdb">PDB</a>)Predicted binding mode of 16b in the ATP pocket of JAK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_005.pdb">PDB</a>)Predicted binding mode of 6a in the active site of HDAC6; surface representation of 6a in the active site of HDAC6 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_006.pdb">PDB</a>)Predicted binding mode of 15d in the active site of HDAC6 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_007.pdb">PDB</a>)Predicted binding mode of 16b in the active site of HDAC6 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_008.pdb">PDB</a>)This article has not yet been cited by other publications.

An Acetyl-Histone Vulnerability in PI3K/AKT Inhibition-Resistant Cancers is Targetable by Both BET and HDAC Inhibitors

Acetyl-CoA biosynthesis drives resistance to histone acetyltransferase inhibition

Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations

Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53

AKT activation controls cell survival in response to HDAC6 inhibition

Class I Histone Deacetylase Inhibition is Synthetic Lethal with BRCA1 Deficiency in Breast Cancer Cells

Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives

EZH2-mediated PP2A Inactivation Confers Resistance to HER2-targeted Breast Cancer Therapy

Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition

Histone acetylation: a key determinant of acquired cisplatin resistance in cancer

AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors

Recent Advances in Multi-target Drugs Targeting Protein Kinases and Histone Deacetylases in Cancer Therapy

Data from Epigenetic Silencing Mediated Through Activated PI3K/AKT Signaling in Breast Cancer

Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer

Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer

Discovery of Novel Pyrrolo[2,3- d ]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors

Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes

Histone acetyltransferases as promising therapeutic targets in glioblastoma resistance

Catalytic-independent functions of INTAC in conferring sensitivity to BET inhibition

Phosphoproteomics Identifies PI3K Inhibitor-selective Adaptive Responses in Pancreatic Cancer Cell Therapy and Resistance

Inhibiting Stromal Class I HDACs Curbs Pancreatic Cancer Progression